Novel Trends with Biologics in Inflammatory Bowel Disease: Sequential and Combined Approaches

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2021 May 17

PMID 33995579

Citations 30

Authors

Giuseppe Privitera

Daniela Pugliese

Loris Riccardo Lopetuso

Franco Scaldaferri

Matteo Neri

Luisa Guidi

Antonio Gasbarrini

Alessandro Armuzzi

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.

Citing Articles

Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan.

Meng M, Kuo C, Lai M, Chiu C, Su M, Chang M J Inflamm Res. 2025; 18:2733-2742.

PMID: 40026313 PMC: 11872097. DOI: 10.2147/JIR.S511309.

Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period.

Markopoulos P, Gaki A, Kokkotis G, Chalakatevaki K, Kioulos N, Kitsou V J Clin Med. 2025; 14(4).

PMID: 40004889 PMC: 11856159. DOI: 10.3390/jcm14041357.

Dual Therapy in Inflammatory Bowel Disease.

Altieri G, Zilli A, Parigi T, Allocca M, Furfaro F, Fiorino G Biomolecules. 2025; 15(2).

PMID: 40001525 PMC: 11853240. DOI: 10.3390/biom15020222.

Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn's Disease in the United States and Europe.

Kershaw J, Sanon M, Kachroo S, Barlow S, Naessens D, Willey C Crohns Colitis 360. 2025; 7(1):otae074.

PMID: 39834357 PMC: 11744185. DOI: 10.1093/crocol/otae074.

Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease.

Bezzio C, Franchellucci G, Savarino E, Mastronardi M, Caprioli F, Bodini G Crohns Colitis 360. 2024; 6(4):otae060.

PMID: 39525291 PMC: 11549494. DOI: 10.1093/crocol/otae060.

References

Tebbutt N, Giraud A, Inglese M, Jenkins B, Waring P, Clay F . Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002; 8(10):1089-97. DOI: 10.1038/nm763. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Ferretti M, Pizarro T, Eisenberg S, Nast C, Cominelli F . Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest. 1994; 94(1):449-53. PMC: 296330. DOI: 10.1172/JCI117345. View

Gui X, Li J, Ueno A, Iacucci M, Qian J, Ghosh S . Histopathological Features of Inflammatory Bowel Disease are Associated With Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria. J Crohns Colitis. 2018; 12(12):1448-1458. DOI: 10.1093/ecco-jcc/jjy116. View

Alsoud D, Vermeire S, Verstockt B . Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. Curr Opin Pharmacol. 2020; 55:17-30. DOI: 10.1016/j.coph.2020.09.002. View

Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T . Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010; 45(10):999-1007. DOI: 10.1007/s00535-010-0245-1. View

Alric H, Amiot A, Kirchgesner J, Treton X, Allez M, Bouhnik Y . The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020; 51(10):948-957. DOI: 10.1111/apt.15706. View

Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E . No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis. Clin Gastroenterol Hepatol. 2020; 19(4):668-679.e8. DOI: 10.1016/j.cgh.2020.06.071. View

Zhang B, Gulati A, Alipour O, Shao L . Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2020; 14(10):1413-1423. PMC: 7533897. DOI: 10.1093/ecco-jcc/jjaa087. View

10.

Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R . Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999; 163(1):143-7. View

11.

Burisch J, Kiudelis G, Kupcinskas L, Kievit H, Andersen K, Andersen V . Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018; 68(3):423-433. DOI: 10.1136/gutjnl-2017-315568. View

12.

Ungaro R, Aggarwal S, Topaloglu O, Lee W, Clark R, Colombel J . Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2020; 51(9):831-842. PMC: 7160034. DOI: 10.1111/apt.15685. View

13.

Kwapisz L, Raffals L, Bruining D, Pardi D, Tremaine W, Kane S . Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2020; 19(3):616-617. DOI: 10.1016/j.cgh.2020.02.017. View

14.

Borghaei H, Langer C, Paz-Ares L, Rodriguez-Abreu D, Halmos B, Garassino M . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020; 126(22):4867-4877. PMC: 7692929. DOI: 10.1002/cncr.33142. View

15.

Feuerstein J, Isaacs K, Schneider Y, Siddique S, Falck-Ytter Y, Singh S . AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020; 158(5):1450-1461. PMC: 7175923. DOI: 10.1053/j.gastro.2020.01.006. View

16.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

17.

Cominelli F, Nast C, Clark B, Schindler R, Lierena R, Eysselein V . Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990; 86(3):972-80. PMC: 296817. DOI: 10.1172/JCI114799. View

18.

Borg-Bartolo S, Boyapati R, Satsangi J, Kalla R . Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020; 9. PMC: 6993839. DOI: 10.12688/f1000research.20928.1. View

19.

Olbjorn C, Rove J, Jahnsen J . Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Paediatr Drugs. 2020; 22(4):409-416. PMC: 7383034. DOI: 10.1007/s40272-020-00396-1. View

20.

Glassner K, Oglat A, Duran A, Koduru P, Perry C, Wilhite A . The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020; 21(5):264-271. DOI: 10.1111/1751-2980.12867. View